Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000047190
Ethics application status
Approved
Date submitted
10/01/2019
Date registered
14/01/2019
Date last updated
13/12/2022
Date data sharing statement initially provided
14/01/2019
Date results information initially provided
7/01/2020
Type of registration
Prospectively registered
Titles & IDs
Public title
Pentosan Polysulphate (PPS) for Dyslipidaemia in Knee Osteoarthritis
Query!
Scientific title
Pentosan Polysulphate (PPS) for Dyslipidaemia in Knee Osteoarthritis
Query!
Secondary ID [1]
297015
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1226-4185
Query!
Trial acronym
PPS Study
Query!
Linked study record
Not Linked
Query!
Health condition
Health condition(s) or problem(s) studied:
Osteoarthritis
310994
0
Query!
Dyslipidaemia
310996
0
Query!
Condition category
Condition code
Musculoskeletal
309649
309649
0
0
Query!
Osteoarthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
100 mg oral Pentosan polysulphate Capsules calculated as per 10 mg per 1 Kg body weight.for e.g 5 capsules if weight =50-55 Kg, 6 capsules if weight=55-60 Kg
Capsules taken once every 4th day
Monitoring of the Intervention - Paper Diary and e diary through a mobile app (both Android and ios phones)
Query!
Intervention code [1]
313296
0
Treatment: Drugs
Query!
Comparator / control treatment
No Control Group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
318606
0
The primary outcome of interest is the change in serum triglycerides levels
Query!
Assessment method [1]
318606
0
Query!
Timepoint [1]
318606
0
Baseline, 16 weeks post baseline visit
Query!
Secondary outcome [1]
365515
0
Change from baseline in blood Cholesterol through serum assay
Query!
Assessment method [1]
365515
0
Query!
Timepoint [1]
365515
0
6, 26 weeks post baseline visit
Query!
Secondary outcome [2]
365517
0
Changes from baseline in Full blood counts (FBC)
Query!
Assessment method [2]
365517
0
Query!
Timepoint [2]
365517
0
6,16,26 weeks post baseline visit
Query!
Secondary outcome [3]
365518
0
Changes from baseline in Prothrombin time (PT) through plasma assay
Query!
Assessment method [3]
365518
0
Query!
Timepoint [3]
365518
0
6,16,26 weeks post baseline visit
Query!
Secondary outcome [4]
365519
0
Composite changes from baseline in Self-reported outcomes of pain, stiffness and functional status measured using the Knee Osteoarthritis Outcome Score (KOOS)
Query!
Assessment method [4]
365519
0
Query!
Timepoint [4]
365519
0
6,16,26 weeks post baseline visit
Query!
Secondary outcome [5]
365520
0
Changes from Baseline in Severity Knee Pain Score
Query!
Assessment method [5]
365520
0
Query!
Timepoint [5]
365520
0
6,16,26 weeks post baseline visit
Query!
Secondary outcome [6]
365521
0
Composite Changes from baseline in Sub-chondral bone structure,density, vascularity by MRI
Query!
Assessment method [6]
365521
0
Query!
Timepoint [6]
365521
0
26 weeks post baseline visit
Query!
Secondary outcome [7]
365576
0
Changes from baseline in Activated Partial thromboplastin time (APTT) through plasma assay
Query!
Assessment method [7]
365576
0
Query!
Timepoint [7]
365576
0
6,16,26 weeks post baseline visit
Query!
Secondary outcome [8]
365577
0
Changes from baseline in D-Dimer through plasma assay
Query!
Assessment method [8]
365577
0
Query!
Timepoint [8]
365577
0
6,16,26 weeks post baseline visit
Query!
Eligibility
Key inclusion criteria
A. Male or female patients minimum of 45 years or more;
B. Are able to give written informed consent and to participate fully in the interventions and follow-up procedures including travel to the Royal North Shore Hospital;
C. Have history of primary hypercholesterolemia and total fasting cholesterol above 5.0mmol/L at screening;
D. Have any symptoms associated with OA of the knee for at least 6 months prior to screening visit and confirmation of OA based on the clinical and radiological criteria of American College of Rheumatology Criteria for OA (Altman et al, 1986) of the knee prior or at screening.
E. Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee based on knee radiograph performed at screening or within six months of the screening visit;
F. Have Index knee pain on most days over the last month.
G. Knee Pain Severity Scale above 4 using an 11-point (0-10) numerical severity scale where 0 is no pain at all and 10 is worst possible pain in the last 48 hours at baseline visit;
(If both knees are affected by OA then the most symptomatic knee will be considered the index knee. If both knees are equally affected, the index knee will be determined by the Investigator.)
H. BMI<40 kg/m2 at screening visit;
I. Agree to maintain their usual activity level and diet throughout the study;
J. Female of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation;
Query!
Minimum age
45
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
A. Documented history of Fibromyalgia, Reiter’s syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease;
B. Known hypersensitivity to Pentosan Polysulfate or related compounds (e.g. heparin);
C. Any unstable concurrent clinically significant acute, chronic medical conditions or abnormal laboratory findings that, in the judgment of the Investigator, would jeopardise the safety of the patient, interfere with the objectives of the protocol, or affect the patients compliance with the study requirements, as determined by the investigator;
D. Contraindications for MRI including but not limited to pacemaker, metal sutures, presence of shrapnel, or claustrophobia;
E. Current or a recent history (within last 12 months) of bleeding (a gastric or duodenal ulcer or suspicion of GI tract bleeding) or menorrhagia;
F. Haemophilia ;
G. Planned / anticipated invasive procedure (or surgery) within 6 months;
H. Recent surgery;
I. Bilateral Knee replacement
J. Concurrent heparin or oral anti-coagulant therapy;
K. Concurrent therapy with lipid –modifying drugs for hypercholesterolemia;
L. Female patients who are pregnant, nursing or intend to get pregnant;
M. Use of prohibited pain medication( see below)
• Oral non-steroidal anti-inflammatory drugs (NSAIDs)
• Aspirin (>325 mg per day)
• Centrally-acting pain medications (e.g., pregabalin, gabapentin, duloxetine)
• Opioids (e.g. tramadol)
• Topical therapies (e.g., NSAIDs ) applied to the index knee
• Muscle relaxants (e.g. tetrazepam, diazepam)
N. Prohibited Concomitant Medications:
• Lipid-modifying drugs: statins ( e.g. atorvastatin, pravastatin and simvastatin) or ezetimibe (Ezetrol)
• Anticoagulants including heparin, warfarin, apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto)
• Biological/ disease –modifying anti-rheumatic drugs for arthritis
• Steroid drugs for systematic use
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Descriptive statistics of baseline characteristics will be provided; continuous variables will be summarised in terms of means and standard deviation (SD) where appropriate or median (range), categorical variables will be presented as frequency (percentage).
The baseline and 4-month serum triglyceride (TG) measurements will be summarised as mean and standard deviation. The change in serum TG between the baseline and 4-month assessment will be summarised as mean with corresponding 95% confidence intervals and assessed using a paired t-test.
Secondary outcomes will be summarised in terms of means and standard deviation at each time point and the change in outcome between baseline and follow-up assessments will be summarised in terms of mean (95% CI) and assessed using a paired t-test. To investigate the relationship between the change in lipid levels and change in clinical outcomes across assessments, general estimating equation (GEE) models will be used including time, clinical outcome and adjusting for baseline lipid level.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/02/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
1/11/2019
Query!
Date of last data collection
Anticipated
30/04/2020
Query!
Actual
20/04/2020
Query!
Sample size
Target
38
Query!
Accrual to date
Query!
Final
38
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
12846
0
Royal North Shore Hospital - St Leonards
Query!
Recruitment postcode(s) [1]
25321
0
2065 - St Leonards
Query!
Funding & Sponsors
Funding source category [1]
301584
0
Commercial sector/Industry
Query!
Name [1]
301584
0
Sylvan Scientific Pty Ltd
Query!
Address [1]
301584
0
ABN 26 112 022 849
109-111 Bronte Road, Bondi Junction,
New South Wales, 2022,
AUSTRALIA
Query!
Country [1]
301584
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Sydney
Query!
Address
F 23, Administration building, Corner of the eastern Avenue and the city road
Camperdown, NSW 2006
Query!
Country
Australia
Query!
Secondary sponsor category [1]
301281
0
None
Query!
Name [1]
301281
0
Query!
Address [1]
301281
0
Query!
Country [1]
301281
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
302313
0
Northern Sydney Local Health District Human Research Ethics Committee (EC00112)
Query!
Ethics committee address [1]
302313
0
Research Office
Kolling Building, Level 13
Royal North Shore Hospital
St Leonards
NSW 2065
Tel (02) 9926 4590
Fax (02) 9926 6179
Query!
Ethics committee country [1]
302313
0
Australia
Query!
Date submitted for ethics approval [1]
302313
0
01/03/2018
Query!
Approval date [1]
302313
0
28/06/2018
Query!
Ethics approval number [1]
302313
0
HREC/18/HAWKE/73
Query!
Summary
Brief summary
This study aims to determine whether oral delivery of PPS drug will lower lipid levels in patients with knee OA. We are also interested to investigate if the improvement in dyslipidaemia might lead to improving OA symptoms and slowing disease progression, as measured by function, pain and MRI, in patients with mild to moderate knee osteoarthritis.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
89786
0
Prof David Hunter
Query!
Address
89786
0
Department of Rheumatology,
Clinical Administration 7 C
Royal North Shore Hospital
St. Leonards, NSW 2065
Query!
Country
89786
0
Australia
Query!
Phone
89786
0
+61 2 9463 1887
Query!
Fax
89786
0
+61 2 9463 1077
Query!
Email
89786
0
[email protected]
Query!
Contact person for public queries
Name
89787
0
Ms Sonika Virk
Query!
Address
89787
0
Department of Rheumatology,
Clinical Administration 7 C
Royal North Shore Hospital
St. Leonards, NSW 2065
Query!
Country
89787
0
Australia
Query!
Phone
89787
0
+61 2 9926 7821
Query!
Fax
89787
0
+61 2 9463 1077
Query!
Email
89787
0
[email protected]
Query!
Contact person for scientific queries
Name
89788
0
Prof David Hunter
Query!
Address
89788
0
Department of Rheumatology,
Clinical Administration 7 C
Royal North Shore Hospital
St. Leonards, NSW 2065
Query!
Country
89788
0
Australia
Query!
Phone
89788
0
+61 2 9463 1887
Query!
Fax
89788
0
Query!
Email
89788
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Study results article
Yes
The abstract was published in VOLUME 30, SUPPLEMEN...
[
More Details
]
Documents added automatically
No additional documents have been identified.
Download to PDF